Fig. 5: Therapeutic efficiency in treating neutropenic thigh infections in vivo.
a, Experimental modelling in vivo. b,c, Bacterial counting in thigh tissues of mice infected by CRAB QLH-2022-637 (b) and MRSA QLH-2022-718 (c). For CRAB infection: sterile water (n = 8), polymyxin B (n = 10), g_AMP14 (n = 7), g_AMP33 (n = 9), g_AMP41 (n = 7), g_AMP42 (n = 7), m_AMP46 (n = 7), m_AMP76 (n = 8). For MRSA infection: sterile water (n = 7), vancomycin (n = 8), g_AMP14 (n = 7), g_AMP35 (n = 7), g_AMP41 (n = 7), g_AMP42 (n = 7), m_AMP46 (n = 7), m_AMP76 (n = 6). The lines in each data group represent the first quartile, median and third quartile. Statistical analysis was conducted using two-sided Wilcoxon rank-sum test. Exact P values are provided in Source Data Fig. 5. d, Schematic of the resistance to enzymatic degradation experiment. e, AMPs were exposed for a total period of 4 h to fetal bovine serum that contains several active proteases. Aliquots of the resulting solution were analysed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Experiments were performed in 2 independent replicates. f,g, Resistance acquisition of CRAB QLH-2022-637 (f) and MRSA QLH-2022-718 (g) under 0.5-fold MIC concentrations of AMPs and antibiotics (n = 3 biologically independent replicates). ‘Water#’ represents DNase/RNase-free and sterile water. The schematics in a and d were created with BioRender.com.
